Company Overview and News
BERN (Reuters) - Switzerland’s top law enforcer took on 237 new criminal investigations last year, 25 percent more than in 2016, as one of the world’s most secretive financial centers steps up efforts to tackle international crime.
The Office for National Statistics (ONS) reported that consumer prices in the United Kingdom slipped to the lowest in a year while wages ticked up. Latest data show that the squeeze on U.K. households may be coming to an end, driving chances of a rate hike as early as next month.
Houston, April 19, 2018 (GLOBE NEWSWIRE) -- Shell Midstream Partners, L.P. (NYSE: SHLX) will host a conference call on Thursday, May 3rd at 8:30am CT to discuss 2018 first-quarter financial results. Shell Midstream Partners’ participants will be Kevin Nichols, president and chief executive officer and Shawn Carsten, chief financial officer.
(Bloomberg) -- France's oil major is stepping up its power business, replicating the strategy of European peers as the global shift toward cleaner energy gathers pace.
Talks between Exxon Mobil and Iraq on a multi-billion-dollar infrastructure contract have reached an impasse, Iraqi officials and two industry sources said, in a potential setback to the oil major's ambitions to expand in the country.
LONDON/BASRA, Iraq (Reuters) - Talks between Exxon Mobil (XOM.N) and Iraq on a multi-billion-dollar infrastructure contract have reached an impasse, Iraqi officials and two industry sources said, in a potential setback to the oil major’s ambitions to expand in the country.
French oil major Total has followed the lead of Royal Dutch Shell by deepening its exposure to the household energy sector with a €1.4bn (£1.2bn) deal to buy a utility.
BP p.l.c. (BP - Free Report) intends to maintain a steady emission of carbon without compromising production growth. In fact, the company plans to combat global warming and focus more on clean energy, following consistent requests from investors.
LONDON/AMSTERDAM, April 18 (Reuters) - Dutch energy company Eneco is working with investment bank Citi to advise on its privatisation, which should kick off soon, three sources familiar with the matter said.
ExxonMobil (XOM) is expected to post its 1Q18 results on April 27, 2018. Before we proceed with 1Q18 estimates, let’s recap XOM’s 4Q17 performance versus estimates. In 4Q17, XOM’s revenues missed Wall Street estimates by 11%. Also, the company’s 4Q17 reported EPS (earnings per share) stood at $1.97. On adjusting for tax benefits (due to tax reforms in the US) and asset impairments, ExxonMobil’s adjusted EPS stood at $0.
LONDON (Bloomberg) -- The world’s biggest oil companies, for long typecast as villains of climate change, are seeking to reinvent themselves as environmental pioneers.
April 18 (Reuters) - The long-delayed Browse gas project off Western Australia has gained key support, with partners in the North West Shelf liquefied natural gas (LNG) plant aiming to agree on a tariff by end-June to handle Browse gas, Woodside Petroleum's chief executive said on Wednesday.
On the news front, U.S. supermajor Chevron Corp. (CVX - Free Report) gave its go-ahead to the $5.1 billion second stage of its massive Gorgon LNG project in Western Australia, while oilfield service providers McDermott International, Inc. (MDR - Free Report) and National Oilwell Varco, Inc. (NOV - Free Report) provided first-quarter operational updates.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET